Kevin Thornal joins
Zimmer Biomet Holdings (ZBH) as
Group President of Global Businesses and the Americas. Previously, an executive made a significant stock sale, followed by another from Sang Yi, selling 800 shares. Despite this, ZBH announced a
quarterly dividend of $0.24 for Q2 2025. However, amid tariff uncertainty, ZBH had to
lower its 2025 profit forecast resulting in a share fall. This didn't stop the company from posting a robust performance as one the top Medical Device Stocks.
During Q1 2025, Zimmer Biomet posted strong financial results and completed the
acquisition of Paragon 28. There were changes to the company's board, and ZBH seemed undervalued by 39%, according to an intrinsic calculation.
CE Mark Approval was granted for Zimmer Biomet's RibFix Advantage® Fixation System. However, analysts suggested stronger cash flows were needed before the stock rebounds. Amid various events, ZBH saw a downward trend in its earnings and shareholder returns over the year. However, in the following week, the stock price saw an increase.
Despite some solvency issues, Zimmer Biomet's Q1 earnings beat operating margin dips. Zimmer Biomet enriches its leadership with new additions and flaunts a load of orthopedic & musculoskeletal innovations. Still, ZBH forecasted a below estimate 2025 profit. Despite an earnings downgrade, the retail market stays bullish with Zimmer Biomet eyeing high-growth ASC Expansion with an acquisition, which opens a door to a $5B foot and ankle market.
Zimmer Biomet Holdings ZBH News Analytics from Mon, 12 Aug 2024 07:00:00 GMT to Wed, 18 Jun 2025 02:41:06 GMT -
Rating 3
- Innovation 5
- Information 7
- Rumor 2
